Takmeed-Har-Ratab (Steam Fomentation) with Hijamah-Bil-Shart (wet cupping) in the Management of Knee Osteoarthritis

Synergistic Effect of Takmeed-Har-Ratab (Steam Fomentation) With Hijamah-Bil-Shart (Wet Cupping) in Knee Osteoarthritis: A Randomized Controlled Clinical Study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/091957

Enrollment

Registered

2025-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Takmeed-Har-Ratab (Steam Fomentation) followed by Hijamah-Bil-Shart (Wet Cupping): Four Sessions of Takmeed-Har-Ratab (Steam Fomentation) with Hijamah-bil-Shart (Wet Cupping) in six wee

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed patients of knee osteoarthritis with a Kellgren & Lawrence grade of 1-3 on X-ray of knee joint. 2. Patients between the age of 35 to 65 years. 3. Patients of all genders. 4. Patients with pain intensity score of more than 30 mm on a 100 mm visual analog scale (VAS). 5. Clinically stable patients. 6. Patients who discontinued all NSAIDS or other analgesic medication taken for any other condition, including their knee pain. 7. Patients signed the informed consent and follow the protocol voluntarily.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women. 2. Severely ill patients. 3. History of severe hypertension, CKD, CLD. 4. Patients with uncontrolled Diabetes mellitus (HbA1C more than 7 percent). 5. Body mass index greater than 45kg per meter square. 6. History of significant trauma, infection or presence of hematoma at the site of knee and/ or knee surgery. 7. Active skin lesion or skin disease at the treatment site. 8. Patients having associated conditions like gout and other rheumatic diseases. 9. Patients of bleeding disorders. 10. Patients of anaemia (Hb less than 9gm). 11. Patients taking Anti-coagulants. 12. HIV, HCV and HBsAg positive patients. 13. History of malignancy. 14. Patients taking NSAIDs or corticosteroids (Washout period: NSAIDs - 01 week; Corticosteroids - 4 weeks respectively is required before enrolling patient). 15. Unwilling to participate in the study

Design outcomes

Primary

Measure	Time frame
Change in the severity of symptoms Patients were assessed on day 0, 14th, 28th, 42nd and 56th for intensity of OA symptoms by a) Visual Analog Scale (VAS) for Pain. b) KOOS (Knee injury and OA outcome score) c) SF-12 for quality-of-life assessment. d) AROM (using goniometer) e) Knee circumference (using measuring tape) f) Walking time (10-meter walk test) Timepoint: 0,14,28,42 and 56 days.	—

Secondary

Measure	Time frame
a) CBC with ESR b) hs-CRP Timepoint: 0 and 56 day.	—

Countries

India

Contacts

Public ContactProf Dr Asim Ali Khan

Jamia Hamdard

asimalikhan@jamiahamdard.ac.in9811794448

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026